文章
醫療新知 > 手機能幫助診斷癌症

手機能幫助診斷癌症

19-04-2015

 

索引目錄

美國麻省總醫院(MGH)研究人員開發出一種新的診斷平台,能利用智能手機對腫瘤及其他疾病做出快速、精確的分子診斷,為缺乏先進醫療技術的地區帶來好處。相關論文發表在美國《國家科學院院刊》上.

該平台稱為數字衍射診斷系統(D3),它將一個拍攝組件裝在標準智能手機上,通過全息攝影記錄下高分辨率圖像數據,並將這些數據上傳,經安全、加密的雲端服務器對圖形數據處理分析,然後把結果迅速返回醫療點。D3系統視野比傳統顯微鏡更大,能記錄血液或組織樣本中超過10萬個細胞的數據。

癌症造成的全球負擔,在許多地區限制人們得到病理檢查服務。新興的細胞剖面技術增加了對低成本、便攜式快速診斷方法的需求。”論文合著者、MGH癌症中心與系統生物學中心醫學博士塞薩爾·卡斯特羅說,他們開發的這一平台能以極低成本提供診斷所需的基本特征。

據物理學家組織網13日報道,D3系統的分析原理是,用結合了已知癌相關分子的微珠給血液或組織樣本作標記,拍攝圖像上傳到服務器後,通過分析微珠生成的衍射圖案,探測是否存在特殊分子。微珠的大小、塗層各不相同,能生成獨特的特征標識,D3平台的數字算法能區分細胞和微珠,分析10兆數據用時不到1/900秒。

在對癌細胞的試驗中,研究人員對25名婦女的宮頸活檢樣本進行了分析,D3系統能迅速可靠地把樣本分為高風險、低風險或良性三類;對於細針淋巴腺活檢樣本分析,能精確區分4種病人。結果均被傳統的病理檢查證實。結合蛋白質分析,系統還能靈敏地探測DNA,如人類乳頭狀瘤病毒等。在這些測試中,可在1小時內得到化驗結果,每次只需1.8美元,今後價格還會進一步下降。

“我們期望D3平台能增加癌症篩查的廣度和深度,在資源有限的環境下切實可行,讓人們能負擔得起。”論文高級作者、MGH系統生物學中心主管拉爾夫·維斯萊德說,手機技術在全球日益普及,利用這種優勢,我們的系統能幫助選擇治療方案,減少因病理檢查缺乏而導致的延誤,減少病人定期覆查的需求。
另一名論文高級作者海克·李指出,這一技術未來發展重在三個方面:一是研究D3平台分析其他疾病媒介的蛋白質和DNA標記的能力,包括傳染性病原體和過敏原;二是將軟件與更大的數據庫結合;三是在發展中國家或農村醫療站點指導臨床研究,通過遠程信息共享實現家庭檢查。MGH已經提出了涵蓋D3技術在內的專利申請.

———————————————————————————————–

Cancer BREAKTHROUGH: Smartphone accessory can diagnose disease in less than an hour

A CUTTING-EDGE smartphone accessory could a provide fast and low-cost new way of diagnosing cancer.

 

Data recorded by the smartphone-powered device is then sent for processing in the cloud GETTY•PICTURES POSED BY MODELS

Data recorded by the smartphone-powered device is then sent for processing in the cloud

The device – dubbed a D3 system – includes a battery-powered LED light that allows a standard smartphone to record high-resolution imaging data with its camera.

We expect that the D3 platform will enhance the breadth and depth of cancer screening

Dr Ralph Weissleder

The D3 system, which stands for digital diffraction diagnosis, is capable of recording data on more than 100,000 cells from a blood or tissue sample in a single image. 

Data recorded by the smartphone-powered device is then sent for processing via a secure and encrypted cloud service.

In a pilot scheme for the new system, a correct diagnosis was returned from the cloud servers in less than an hour.

Researchers behind the new system claim the diagnosis costs just £1.25per sample – and will decrease over time.

Study co-lead author Doctor Cesar Castro, of the Massachusetts General Hospital Cancer Center in the United States, said: "The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost, portable and rapid diagnostic approaches that can be delivered at the point of care.

Samples captured and analysed by the pilot D3 systemNATIONAL NEWS

Samples captured and analysed by the pilot D3 system

"The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy, supports the need for molecular profiling strategies that are more accessible to providers, clinical investigators and patients; and we believe the platform we have developed provides essential features at an extraordinary low cost." 

Researchers say the D3 system employs the same technology that is used to make holograms to collect detailed microscopic images for digital analysis of the molecular composition of cells and tissues.

Investigators conducted analysis of cervical biopsy samples from 25 women with abnormal PAP smears.

The D3 analysis correctly categorised biopsy samples as high-risk, low-risk or benign – with each of the results matching those returned by conventional pathologic analysis.

Co-senior author Dr Ralph Weissleder said: "We expect that the D3 platform will enhance the breadth and depth of cancer screening in a way that is feasible and sustainable for resource limited-settings.

"By taking advantage of the increased penetration of mobile phone technology worldwide, the system should allow the prompt triaging of suspicious or high-risk cases that could help to offset delays caused by limited pathology services in those regions and reduce the need for patients to return for follow-up care, which is often challenging for them." 

 

www.express.co.uk/life-style/science-technology/570276/D3-System-Cancer-Smartphone-Accessory-Diagnose-Disease-Hour

 

疑難排解

會員註冊


或許你會想看
慢性淋巴細胞白血病 (CLL) 口服標靶藥 助病人長時間穩定病情
王紹明醫生 中文大學內科及藥物治療學系名譽臨床副教授 「慢性淋巴細胞白血病 (Chronic lymphocy […]
中大全球首證血糖波動不穩的肥胖型糖尿病患者有較高患癌風險 並證實接受一類常用降血壓藥物的糖尿病患者患癌風險則較低
香港中文大學(中大)醫學院利用大數據研究糖尿病患者的患癌風險,首次獲得兩項重要發現。研究團隊發現患有糖尿病並有 […]
中大葉氏家族基金腫瘤學教授陳林教授就職演講「不苦口的良藥」
抗癌治療的副作用為患者帶來巨大的生理和心理壓力,肝膽胰癌症患者更經常因器官受損,比其他癌症患者較易出現相關副作 […]
中大與國際團隊領導肺癌研究 證實Lorlatinib可成為ALK陽性晚期非小細胞肺癌一線治療
香港中文大學(中大)醫學院莫樹錦教授與國際肺癌專家團隊早前針對帶有「間變性淋巴瘤激酶(ALK)基因變異」的晚期 […]
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌 2022年8月8日 1 中大醫學院領導的一項多中心臨床研究發現 […]
新藥Dostarlimab給MMR缺損病人的新希望
新藥Dostarlimab給MMR缺損病人的新希望 [醫療新資訊] MMR缺損對人們有甚麼影響呢﹖為甚麼新藥D […]
【創新科研】中大研新型抗癌免疫療法及可彎曲手術鑽 全國挑戰杯共奪5獎
【創新科研】中大研新型抗癌免疫療法及可彎曲手術鑽 全國挑戰杯共奪5獎 ▲ 左起:病理解剖及細胞學系助理教授鄧銘 […]
芯片上的蠕蟲能視作癌症偵察器﹖
芯片上的蠕蟲能視作癌症偵察器﹖ [癌症資訊新聞] 根據《科學報告》學術期刊發表了一篇研究報告指,科學家利用秀麗 […]
基石藥業胃腸道間質瘤精準靶向藥(avapritinib)在香港正式上市 創新療法有望惠及更多患者
基石藥業胃腸道間質瘤精準靶向藥(avapritinib)在香港正式上市 創新療法有望惠及更多患者   在眾多癌 […]